Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ATXS
stocks logo

ATXS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.482
+9.66%
--
--
-0.573
-1.29%
--
--
-0.585
+2.63%
Estimates Revision
The market is revising Downward the revenue expectations for Astria Therapeutics, Inc. (ATXS) for FY2025, with the revenue forecasts being adjusted by -24.76% over the past three months. During the same period, the stock price has changed by 74.47%.
Revenue Estimates for FY2025
Revise Downward
down Image
-24.76%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.24%
In Past 3 Month
Stock Price
Go Up
up Image
+74.47%
In Past 3 Month
Wall Street analysts forecast ATXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATXS is 20.00 USD with a low forecast of 13.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast ATXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATXS is 20.00 USD with a low forecast of 13.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
7 Hold
0 Sell
Hold
Current: 13.120
sliders
Low
13.00
Averages
20.00
High
35.00
Current: 13.120
sliders
Low
13.00
Averages
20.00
High
35.00
Cantor Fitzgerald
Overweight
to
Neutral
downgrade
2025-11-12
Reason
Cantor Fitzgerald
Price Target
2025-11-12
downgrade
Overweight
to
Neutral
Reason
Cantor Fitzgerald downgraded Astria Therapeutics to Neutral from Overweight.
H.C. Wainwright
Buy -> Neutral
downgrade
2025-10-16
Reason
H.C. Wainwright
Price Target
2025-10-16
downgrade
Buy -> Neutral
Reason
H.C. Wainwright downgraded Astria Therapeutics to Neutral from Buy without a price target after the company agreed to be acquired by BioCryst (BCRX) for a mix of cash and stock representing an implied value of $13 per share.
Citizens JMP
Outperform -> Market Perform
downgrade
2025-10-15
Reason
Citizens JMP
Price Target
2025-10-15
downgrade
Outperform -> Market Perform
Reason
Citizens JMP downgraded Astria Therapeutics (ATXS) to Market Perform from Outperform without a price target afire after the company reached an agreement to be acquired by BioCryst (BCRX) for cash and stock at an implied value of $13 per share, or $700M. The firm views it as highly likely that the transaction will close as announced.
Citizens JMP
Jonathan Wolleben
Outperform
upgrade
$17 -> $27
2025-10-15
Reason
Citizens JMP
Jonathan Wolleben
Price Target
$17 -> $27
2025-10-15
upgrade
Outperform
Reason
Citizens JMP analyst Jonathan Wolleben raised the firm's price target on BioCryst (BCRX) to $27 from $17 and keeps an Outperform rating on the shares. BioCryst is buying Astria Therapeutics (ATXS) to "supercharge" its earnings growth with long- acting HAE candidate navenibart, the analyst tells investors in a research note. The firm expects 3 month and 6 month navenibart doses to hit in Astria's ongoing Phase 3 trial in early 2027 and believe its differentiated, long-acting convenience, coupled with impressive efficacy, will drive broad adoption right as BioCryst's Orladeyo hits its peak penetration.
Wedbush
Outperform -> Neutral
downgrade
$28 -> $13
2025-10-15
Reason
Wedbush
Price Target
$28 -> $13
2025-10-15
downgrade
Outperform -> Neutral
Reason
Wedbush downgraded Astria Therapeutics (ATXS) to Neutral from Outperform with a price target of $13, down from $28, after the company reached an agreement to be acquired by BioCryst (BCRX) for cash and stock at an implied value of $13 per share, or $700M.
RBC Capital
Outperform
maintain
$14 -> $15
2025-10-14
Reason
RBC Capital
Price Target
$14 -> $15
2025-10-14
maintain
Outperform
Reason
RBC Capital raised the firm's price target on BioCryst (BCRX) to $15 from $14 and keeps an Outperform rating on the shares. Following the announced transaction to acquire Astria Therapeutics (ATXS), their conference call discussing terms, and the firm's discussion with BioCryst's management team, RBC has further conviction that despite the near-term dilution tradeoff, this is a very sound deal that should leverage BioCryst's core competencies well, and set up their franchise even better. The firm added that Tuesday's weakness in BioCryst shares presents a compelling buying opportunity.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Astria Therapeutics Inc (ATXS.O) is -5.86, compared to its 5-year average forward P/E of -3.81. For a more detailed relative valuation and DCF analysis to assess Astria Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.81
Current PE
-5.86
Overvalued PE
-1.87
Undervalued PE
-5.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.81
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.23
Undervalued EV/EBITDA
-3.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
8.14
Current PS
0.00
Overvalued PS
44.75
Undervalued PS
-28.47
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

ATXS News & Events

Events Timeline

(ET)
2025-12-03
07:10:00
BioCryst Receives Early Termination for Acquisition of Astria
select
2025-11-06 (ET)
2025-11-06
09:46:40
Astria Therapeutics reveals conclusive findings from the ALPHA-STAR trial
select
2025-10-14 (ET)
2025-10-14
08:57:37
Video: Early Movers Spotlighted by Banks and Dealmakers
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
12-02PRnewswire
Avidity Biosciences Acquired by Novartis for $72 per Share
  • Acquisition Investigation: Halper Sadeh LLC is investigating Avidity Biosciences, Inc. (NASDAQ:RNA) for its sale to Novartis at $72 per share in cash, potentially violating federal securities laws and fiduciary duties to shareholders.
  • Shareholder Rights: The law firm encourages Avidity shareholders to contact them immediately to learn about their rights and options, indicating that shareholder interests may be at risk in the transaction.
  • Merger Scrutiny: Halper Sadeh LLC is also examining the merger between Third Coast Bancshares, Inc. (NYSE:TCBX) and Keystone Bancshares, Inc., which may involve fiduciary duty issues affecting shareholders.
  • Legal Support: The firm offers legal assistance on a contingency fee basis, ensuring that affected investors can seek increased compensation and disclosures without upfront costs, highlighting their commitment to protecting shareholder rights.
[object Object]
Preview
7.0
11-22Globenewswire
Halper Sadeh LLC Urges ATXS, PCH, RYN Shareholders to Reach Out to the Firm Regarding Their Rights

  • Investigation of Companies: Halper Sadeh LLC is investigating Astria Therapeutics, PotlatchDeltic Corporation, and Rayonier Inc. for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed transactions.

  • Details of Transactions: Astria Therapeutics is set to be sold to BioCryst Pharmaceuticals for $8.55 in cash and shares, while PotlatchDeltic will merge with Rayonier, resulting in PotlatchDeltic shareholders owning 46% and Rayonier shareholders owning 54% of the combined company.

  • Legal Rights for Shareholders: Shareholders of the involved companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options regarding the transactions, with the firm offering services on a contingent fee basis.

  • Firm's Background: Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered significant amounts for defrauded investors.

[object Object]
Preview
7.0
11-12PRnewswire
Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights

  • Investigation Announcement: Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales of Heidrick & Struggles, Merus N.V., and Astria Therapeutics.

  • Shareholder Rights: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options, as there may be limited time to enforce these rights.

  • Legal Representation: The firm offers to handle cases on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees.

  • Firm's Background: Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, successfully recovering millions for defrauded investors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Astria Therapeutics Inc (ATXS) stock price today?

The current price of ATXS is 13.12 USD — it has increased 0.23 % in the last trading day.

arrow icon

What is Astria Therapeutics Inc (ATXS)'s business?

Astria Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. It owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.

arrow icon

What is the price predicton of ATXS Stock?

Wall Street analysts forecast ATXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATXS is 20.00 USD with a low forecast of 13.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Astria Therapeutics Inc (ATXS)'s revenue for the last quarter?

Astria Therapeutics Inc revenue for the last quarter amounts to 706.00K USD, decreased % YoY.

arrow icon

What is Astria Therapeutics Inc (ATXS)'s earnings per share (EPS) for the last quarter?

Astria Therapeutics Inc. EPS for the last quarter amounts to -0.55 USD, increased 30.95 % YoY.

arrow icon

What changes have occurred in the market's expectations for Astria Therapeutics Inc (ATXS)'s fundamentals?

The market is revising Downward the revenue expectations for Astria Therapeutics, Inc. (ATXS) for FY2025, with the revenue forecasts being adjusted by -24.76% over the past three months. During the same period, the stock price has changed by 74.47%.
arrow icon

How many employees does Astria Therapeutics Inc (ATXS). have?

Astria Therapeutics Inc (ATXS) has 78 emplpoyees as of December 05 2025.

arrow icon

What is Astria Therapeutics Inc (ATXS) market cap?

Today ATXS has the market capitalization of 747.81M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free